Core Insights - Assertio Holdings reported strong financial results for Q3 2025, with significant growth in net product sales, particularly for Rolvedon, which saw sales increase to $38.6 million from $15.0 million year-over-year [7][2] - The company has narrowed its FY2025 net product sales guidance to a range of $110 million to $112 million and adjusted EBITDA guidance to $14 million to $16 million [5][1] - Paul Schwichtenberg has been promoted to President and COO, indicating a strategic focus on operational efficiency and commercial execution [6][8] Financial Performance - Rolvedon net product sales reached $38.6 million in Q3 2025, a 157% increase from $15.0 million in Q3 2024 [7] - Sympazan net product sales grew to $2.8 million in Q3 2025, up from $2.6 million in the prior-year quarter [7] - Indocin net product sales decreased to $4.8 million in Q3 2025 from $5.7 million in Q3 2024 due to generic competition [7] - Gross margin was reported at 72%, down from 74% in the prior-year quarter, attributed to a higher proportion of Rolvedon sales [7] - Adjusted EBITDA for Q3 2025 was $20.9 million, significantly up from $4.4 million in Q3 2024 [7] Guidance and Outlook - The updated guidance for FY2025 reflects the impact of the Rolvedon pull-forward and improved visibility into expected performance for the remainder of the year [5][2] - The company expects uninterrupted patient supply of Rolvedon, with regular sales of the newly labeled product anticipated to begin in Q2 2026 [7] Leadership Changes - Paul Schwichtenberg's promotion to President and COO is aimed at enhancing commercial strategies and driving future growth [8][6] - Schwichtenberg has a history of leadership roles within the company, focusing on operational and commercial execution [8]

Market Overview - The Tel Aviv Stock Exchange experienced a flat day with the Tel Aviv 35 Index decreasing by 0.03% to 3,334.88 points, while the Tel Aviv 125 Index increased by 0.07% to 3,391.87 points. The BlueTech Global Index fell by 0.44% to 591.20 points. The All Bond corporate bond index slightly decreased by 0.01% to 418.02 points. Total turnover in equities was NIS 1.41 billion and in bonds was NIS 2.09 billion [1]. Currency Exchange Rates - The shekel-dollar exchange rate was set 0.369% higher at NIS 3.265/$, and the shekel-euro rate was set 0.518% higher at NIS 3.766/€ [2]. Company Performance - Bank Leumi led the market with a decline of 0.33% on the highest trading turnover. Tower Semiconductor Ltd. experienced the largest drop on the Tel Aviv 35 Index, falling by 3.88%. Other notable declines included Teva Pharmaceutical Industries Ltd. at 1.91%, Nice at 2.97%, and Energean plc at 3.37% [3]. - NextVision had a strong debut, rising by 7.09% on its first day of trading on the Tel Aviv 35 Index, marking the largest increase for the day. Other companies that saw gains included Israel Discount Bank at 0.94%, Bank Hapoalim at 0.57%, and Phoenix Finance at 1.96% [4].

Core Insights - Takeda has presented new data indicating that mezagitamab (TAK-079) shows sustained effects on kidney function in patients with primary IgA nephropathy, maintaining stable kidney function (eGFR) 18 months after the last treatment dose [1][2][4] Group 1: Clinical Study Results - In a Phase 1b open-label study, kidney function remained stable in patients with IgA nephropathy through Week 96, with a mean change in eGFR from baseline of +2.5 (95% CI: 1.8, +7.6; n=12) [4] - Patients experienced a 55.2% mean reduction in proteinuria (95% CI: 30.2, 72.6; n=13) and a 50.1% reduction in Gd-IgA1 levels by Week 96 [4][5] - Hematuria resolved in 60% of patients by Week 96, indicating significant improvements in kidney health [4] Group 2: Safety and Tolerability - Mezagitamab was generally well tolerated, with no serious adverse events, including serious hypersensitivity or injection-related reactions reported [5][6] - The study did not identify any new safety concerns, reinforcing the potential of mezagitamab as a treatment for autoimmune diseases like IgA nephropathy [5] Group 3: Future Development and Designations - Takeda is currently conducting pivotal Phase 3 clinical trials for mezagitamab in both primary IgA nephropathy and chronic immune thrombocytopenia, with patient enrollment ongoing [6] - Mezagitamab received Orphan Drug Designation from the European Medicines Agency for primary IgA nephropathy and Breakthrough Therapy Designation from the U.S. FDA for chronic immune thrombocytopenia [6]

there's no there's not as much innovation over there and if we import those price controls here the argument is from the pharmaceutical industry that they're not going to be able to afford innovation and testing out new drug is is that totally false or is the truth somewhere in the middle >> I think that specific narrative is false and I my evidence for that is all these drug companies Eli Liy and Novo Norris are well-run companies their CEOs were in the Oval Office they came there willingly they were not h ...

Welcome to CBC. com. I'm Frank Colin, anchor of Worldwide Exchange.We are taking a look at the ETF market, which as of today has $1.13% trillion in net inflows, just a tick below the record set last year. And we are on pace for another record year this year. With that, I want to bring in my guest for today.It's Anaket Ulfra, head of their ETF business. Anakette, thanks for joining us. >> Thanks for having me, Frank.Um, first off, let me talk to you about the fact that ETF inflows are going to hit a record f ...

>> IT IS 10:00 A.M. IN LONDON AND 5:00 A.M. IN NEW YORK CITY. LET US GET STARTED WITH WHAT YOU NEED TO KNOW. A TERRIBLE WEEK FOR TECH. VALUATION WORRIES KNOCKING GLOBAL EQUITIES. MID-CAP STOCKS SELLOFF DESPITE POCKETS OF POSITIVE EARNINGS REPORTS. THE TESLA TRILLIONAIRE. SHAREHOLDERS APPROVE A ONE TRILLION DOLLAR COMPENSATION PACKAGE TO ELON MUSK MARKING THE LARGEST PAYOFF EVER AWARDED TO A CEO. AIRLINES BEGIN CANCELING FLIGHTS AS THE GOVERNMENT SHUTDOWN DRAGS ON. WE ARE LIVE ON THE GROUND. LET US GET A QUI ...

Nov 6, 2025 7:30 AM Eastern Standard Time Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025 Share JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a primary focus on women's health, will release its third quarter 2025 financial results on November 10, 2025, prior to the company's webcast and conference call scheduled for 8:30 a.m. ET. The webcast and conference call will be hosted by Carrie Cox, Organon's Executive Board Chair ...

Core Insights - Johnson & Johnson will participate in the Citi's 2025 Global Healthcare Conference on December 3, 2025, with management engaging in a Fireside Chat at 11:15 a.m. Eastern Time [1] - A live audio webcast of the presentation will be available on Johnson & Johnson's Investor Relations website, with an archived edition accessible later that day [2] - The company also announced its participation in the 7th Annual Wolfe Research Healthcare Conference on November 17, 2025, with a Fireside Chat scheduled for 10:40 a.m. Eastern Time [3] Company Developments - Johnson & Johnson announced its intent to separate its Orthopaedics business to enhance strategic and operational focus, aiming to drive value for stakeholders and strengthen its position in Innovative Medicine and MedTech [6]

A judge denied Pfizer’s request to temporarily block Novo’s $10 billion bid to acquire the obesity startup Metsera, saying the US pharmaceutical company’s objections to the deal don’t warrant a delay https://t.co/MQfqucbmeh ...

A judge denied Pfizer’s request to temporarily block Novo’s $10 billion bid to acquire the obesity startup Metsera, saying the US pharmaceutical company’s objections to the deal don’t warrant a delay https://t.co/sKEGr9srqe ...